|
Characteristics of endogenous invasive MRSA infections |
||||||||
| Patient no. |
Type of infection |
Period |
Date of infection |
Delay between admission and infection (days) |
Delay between positive MRSA screening and infection (days) |
Antibiotic treatment (Y/N) |
Death (Y/N) |
Time between infection and death (days) |
|
|
||||||||
| 1 |
Pneumonia |
P1 |
4 Sep 2000 |
26 |
7 |
Y (vancomycin) |
N |
|
| 2 |
Bacteraemia |
P2 |
14 Aug 2001 |
8 |
7 |
Y (vancomycin) |
Y |
15 |
| 3 |
Pneumonia |
P2 |
29 Aug 2001 |
37 |
6 |
Y (vancomycin) |
N |
|
| 4 |
Pneumonia |
P2 |
29 Aug 2001 |
13 |
2 |
N |
Y |
0 |
| 5 |
Endocarditis |
P2 |
10 Oct 2001 |
6 |
6 |
Y (vancomycin) |
N |
|
| 6 |
Bacteraemia |
P2 |
24 Dec 2001 |
18 |
13 |
Y (vancomycin) |
N |
|
| 7 |
Bacteraemia |
P2 |
16 Feb 2002 |
8 |
5 |
Y (vancomycin) |
N |
|
| 8 |
Pneumonia |
P2 |
1 Apr 2002 |
3 |
2 |
Y (vancomycin) |
N |
|
| 9 |
Pneumonia |
P2 |
6 Jun 2002 |
13 |
13 |
Y (vancomycin) |
N |
|
| 10 |
Bacteraemia |
P2 |
22 Jun 2002 |
26 |
26 |
Y (vancomycin) |
N |
|
| 11 |
Pneumonia |
P2 |
6 Feb 2003 |
13 |
3 |
Y (linezolid) |
Y |
7 |
| 12 |
Pneumonia |
P2 |
24 Mar 2003 |
7 |
5 |
Y (vancomycin) |
N |
|
|
MRSA, methicillin-resistant Staphylococcus aureus; P1, June 1999 to May 2001; P2, June 2001 to May 2003. | ||||||||
Muller et al. Critical Care 2005 9:R246 doi:10.1186/cc3512 |
||||||||